Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Thursday.

Separately, Zacks Investment Research raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research report on Friday, March 17th.

Shares of Marinus Pharmaceuticals (MRNS) traded up 5.97% during midday trading on Thursday, reaching $1.42. The company’s stock had a trading volume of 2,729,119 shares. Marinus Pharmaceuticals has a 12-month low of $0.82 and a 12-month high of $2.73. The company’s market capitalization is $31.84 million. The company’s 50-day moving average price is $1.28 and its 200 day moving average price is $1.30.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Monday, May 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.06. On average, equities research analysts forecast that Marinus Pharmaceuticals will post ($1.00) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at

Several hedge funds and other institutional investors have recently made changes to their positions in the company. KCG Holdings Inc. raised its position in shares of Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 14,692 shares in the last quarter. Jennison Associates LLC bought a new stake in Marinus Pharmaceuticals during the first quarter valued at $690,000. Granite Point Capital Management L.P. bought a new stake in Marinus Pharmaceuticals during the first quarter valued at $1,372,000. Finally, Nexthera Capital LP bought a new stake in Marinus Pharmaceuticals during the first quarter valued at $1,416,000. 32.69% of the stock is owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.